Galmed Pharmaceuticals Ltd (GLMD) Stock Analysis

Galmed Pharmaceuticals Ltd (GLMD) is a publicly traded company in the HEALTHCARE sector. It trades at $0.69, carries a market capitalization of $4.80M. This page summarizes the public market data, fundamentals, and frequently asked questions for GLMD, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.69
• Market Cap: $4.80M
• EPS: $-2.39
• 52-Week High: $2.34
• 52-Week Low: $0.41

Market Sentiment

Galmed Pharmaceuticals Ltd currently has a Bullish sentiment score of 0.46.

About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel, focused on developing innovative therapies for liver diseases such as non-alcoholic steatohepatitis (NASH). The company boasts a robust pipeline backed by its proprietary drug platform, targeting substantial unmet medical needs in hepatology. Galmed's lead candidate, Aramchol, has demonstrated promising clinical results, enhancing its positioning for future growth opportunities ...

GNG Research Analysis

GNG Research scores Galmed Pharmaceuticals Ltd (GLMD) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GLMD.

Frequently Asked Questions

Does GLMD pay dividends?

Galmed Pharmaceuticals Ltd (GLMD) does not currently pay a regular dividend.

What is GLMD's market cap?

Galmed Pharmaceuticals Ltd (GLMD) has a market capitalization of $4.80M with a current stock price of $0.69.